Cystadenocarcinoma, Serous

"Cystadenocarcinoma, Serous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)

Descriptor ID	D018284
MeSH Number(s)	C04.557.470.200.025.480.240 C04.557.470.590.480.240
Concept/Terms	Cystadenocarcinoma, Serous Cystadenocarcinoma, Serous Cystadenocarcinomas, Serous Serous Cystadenocarcinoma Serous Cystadenocarcinomas

Below are MeSH descriptors whose meaning is more general than "Cystadenocarcinoma, Serous".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Neoplasms, Glandular and Epithelial [C04.557.470]
Carcinoma [C04.557.470.200]
Adenocarcinoma [C04.557.470.200.025]
Cystadenocarcinoma [C04.557.470.200.025.480]
Cystadenocarcinoma, Serous [C04.557.470.200.025.480.240]
Neoplasms, Cystic, Mucinous, and Serous [C04.557.470.590]
Cystadenocarcinoma [C04.557.470.590.480]
Cystadenocarcinoma, Serous [C04.557.470.590.480.240]

Below are MeSH descriptors whose meaning is related to "Cystadenocarcinoma, Serous".

Below are MeSH descriptors whose meaning is more specific than "Cystadenocarcinoma, Serous".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cystadenocarcinoma, Serous" by people in this website by year, and whether "Cystadenocarcinoma, Serous" was a major or minor topic of these publications.

Bar chart showing 13 publications over 11 distinct years, with a maximum of 2 publications in 2020 and 2026

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	1	1
2007	1	0	1
2008	1	0	1
2009	1	0	1
2011	1	0	1
2012	0	1	1
2019	1	0	1
2020	1	1	2
2021	1	0	1
2023	1	0	1
2026	2	0	2

Below are the most recent publications written about "Cystadenocarcinoma, Serous" by people in Profiles.

Balkwill FR, Laumont CM, Burdett N, Le Saux O, Garsed DW, Grither WR, Nijhuis AM, Recouvreux MS, Kang Z, Zhang R, Chiappinelli KB, Lee JS, Laniti DD, McNeish I, Ahmed AA, Rottapel R, Conejo-Garcia JR, Odunsi K, Pharoah PDP, Zamarin D, Ishak CA, Fotopoulou C, Buckanovich RJ, Labidi-Galy I, Brenton JD, Lengyel E, Cook DP, George SHL, Lheureux S, Drapkin R, Nephew KP, Adams S, Pathania S, Nelson BH, F?rkkil? A, Fuh K, Neel BG, Bowtell DD. Rethinking ovarian cancer III: the past decade and future directions. Nat Rev Cancer. 2026 Jun; 26(6):452-471.

View in: PubMed
Porter RL, Zhou Y, Eskndir N, Hayes M, Polak M, Lee EK, Krasner C, Campos S, Wright AA, Liu JF, Stover EH, Sawyer H, Xiong N, Pfaff KL, Rodig SJ, Tayob N, Zweizig S, John V, Veneris J, Matulonis UA, Konstantinopoulos PA. Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial. Nat Commun. 2026 Mar 26; 17(1).

View in: PubMed
Galhenage P, Zhou Y, Perry E, Loc B, Fietz K, Iyer S, Reinhardt F, Da Silva T, Botchkarev V, Chen J, Crum CP, Weinberg RA, Pathania S. Replication stress and defective checkpoints make fallopian tube epithelial cells putative drivers of high-grade serous ovarian cancer. Cell Rep. 2023 10 31; 42(10):113144.

View in: PubMed
Ersoy E, Cao QJ, Otis CN. HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas. Int J Gynecol Pathol. 2022 07 01; 41(4):313-319.

View in: PubMed
Iyer S, Zhang S, Yucel S, Horn H, Smith SG, Reinhardt F, Hoefsmit E, Assatova B, Casado J, Meinsohn MC, Barrasa MI, Bell GW, P?rez-Villatoro F, Huhtinen K, Hynninen J, Oikkonen J, Galhenage PM, Pathania S, Hammond PT, Neel BG, Farkkila A, P?pin D, Weinberg RA. Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy. Cancer Discov. 2021 02; 11(2):384-407.

View in: PubMed
Acosta AM, Sholl LM, Cin PD, Howitt BE, Otis CN, Nucci MR. Malignant tumours of the uterus and ovaries with Mullerian and germ cell or trophoblastic components have a somatic origin and are characterised by genomic instability. Histopathology. 2020 Nov; 77(5):788-797.

View in: PubMed
Clarke CL, Kushi LH, Chubak J, Pawloski PA, Bulkley JE, Epstein MM, Burnett-Hartman AN, Powell B, Pearce CL, Spencer Feigelson H. Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients. Cancer Epidemiol Biomarkers Prev. 2019 05; 28(5):996-999.

View in: PubMed
McGunigal M, Liu J, Kalir T, Chadha M, Gupta V. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis. Int J Gynecol Cancer. 2017 01; 27(1):85-92.

View in: PubMed
Albuquerque K, Patel M, Liotta M, Harkenrider M, Guo R, Small W, Ronald P. Long-term Benefit of Tumor Volume-Directed Involved Field Radiation Therapy in the Management of Recurrent Ovarian Cancer. Int J Gynecol Cancer. 2016 May; 26(4):655-60.

View in: PubMed
Georgakopoulos P, Mehmood S, Akalin A, Shroyer KR. Immunohistochemical localization of HE4 in benign, borderline, and malignant lesions of the ovary. Int J Gynecol Pathol. 2012 Nov; 31(6):517-23.

View in: PubMed

People

Explore

Similar Concepts

Top Journals